Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities

被引:84
作者
Sadée, W
Wang, DX
Bilsky, EJ
机构
[1] Ohio State Univ, Coll Med & Publ Hlth, Dept Pharmacol, Columbus, OH 43210 USA
[2] Univ New England, Coll Osteopath Med, Dept Pharmacol, Biddeford, ME 04005 USA
关键词
opioid receptors; basal activity; neutral antagonist; inverse agonist;
D O I
10.1016/j.lfs.2004.10.024
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The mu opioid receptor (MOR, OPRM) - the principal receptor involved in narcotic addiction- has been shown to display basal (spontaneous, constitutive) signaling activity. Interaction with other signaling proteins, such as calmodulin, regulates basal MOR activity. Providing a mechanism for long-lasting regulation, basal MOR activity potentially plays a key role in addiction, in combination with gene regulation and synaptic remodeling. Recent results support a link to physical dependence - one of the main manifestations of addiction to drugs of abuse. The prototypical opioid antagonists, naloxone and naltrexone, were shown to act as inverse agonists in the morphine-dependent state (i.e., they suppress basal MOR signaling) and thereby appear to elicit or contribute to precipitated withdrawal. This affords the opportunity to explore therapeutic applications for neutral antagonists (blocking agonists at MOR without affecting basal activity) with reduced adverse effects. Neutral antagonists are promising drug candidates in the treatment of addiction and overdose, and of peripheral adverse effects of narcotic analgesics. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1427 / 1437
页数:11
相关论文
共 58 条
[1]   Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity [J].
Aceto, MD ;
Harris, LS ;
Bowman, ER .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 338 (03) :215-223
[2]   Inverse agonism gains weight [J].
Adan, RAH ;
Kas, MJH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (06) :315-321
[3]  
ARDEN JR, 1995, J NEUROCHEM, V65, P1636
[4]  
BARKER EL, 1994, J BIOL CHEM, V269, P11687
[5]   Ligands for κ-opioid and ORL1 receptors identified from a conformationally constrained peptide combinatorial library [J].
Becker, JAJ ;
Wallace, A ;
Garzon, A ;
Ingallinella, P ;
Bianchi, E ;
Cortese, R ;
Simonin, F ;
Kieffer, BL ;
Pessi, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) :27513-27522
[6]   μ-opioid receptor-mediated ERK activation involves calmodulin-dependent epidermal growth factor receptor transactivation [J].
Belcheva, MM ;
Szùcs, M ;
Wang, DX ;
Sadee, W ;
Coscia, CJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33847-33853
[7]  
Bilsky EJ, 1996, J PHARMACOL EXP THER, V277, P484
[8]   Binding of calmodulin to the D2-dopamine receptor reduces receptor signaling by arresting the G protein activation switch [J].
Bofill-Cardona, E ;
Kudlacek, O ;
Yang, Q ;
Ahorn, H ;
Freissmuth, M ;
Nanoff, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (42) :32672-32680
[9]   μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence [J].
Bohn, LM ;
Gainetdinov, RR ;
Lin, FT ;
Lefkowitz, RJ ;
Caron, MG .
NATURE, 2000, 408 (6813) :720-723
[10]  
Bohn LM, 2002, J NEUROSCI, V22, P10494